J Korean Soc Transplant.  2015 Mar;29(1):9-15. 10.4285/jkstn.2015.29.1.9.

Management of Opportunistic Infections after Organ Transplantation

• Kim IK
• Ju MK

• KMID: 2202558
• DOI: http://doi.org/10.4285/jkstn.2015.29.1.9

Abstract

Solid organ transplantation is a therapeutic option for end-stage organ diseases. However, complications including infection and graft rejection, which are related to immunosuppressive therapy, remain the major causes of morbidity and mortality following solid organ transplantation. The optimal approach to infection in solid organ transplant recipients is prevention; failing this, prompt and aggressive diagnosis and therapy are essential. In addition, the epidemiology of infections after solid organ transplantation has shifted as a result of changes in immunosuppressive strategies and improved survival. Immunosuppression must be linked with appropriate vaccinations, donor and recipient screening, patient education regarding infectious risks and lifestyle, monitoring, and antimicrobial prophylaxis.

Keyword

Organ transplantation; Infection; Immunosuppression

MeSH Terms

Diagnosis
Epidemiology
Graft Rejection
Humans
Immunosuppression
Life Style
Mass Screening
Mortality
Opportunistic Infections*
Organ Transplantation*
Patient Education as Topic
Tissue Donors
Transplants*
Vaccination

Reference

References

1). West M, Pirenne J, Chavers B, Gillingham K, Sutherland DE, Dunn DL, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant. 1999; 13:318–23.

2). Apaydin S, Altiparmak MR, Saribaş S, Oztü rk R. Prevalence of clostridium difficile toxin in kidney transplant recipients. Scand J Infect Dis. 1998; 30:542.

3). Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant. 2002; 16:1–8.

4). Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167:603–62.

5). Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992; 52:453–7.

6). Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999; 39:91–6.

7). Naraqi S. Cytomegaloviruses. Belshe RB, editor. Textbook of human virology. 2nd ed.St. Louis: Mosby Year Book;1991. p. 889–924.

8). Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001; 12:848–55.

9). Mwintshi K, Brennan DC. Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Rev Anti Infect Ther. 2007; 5:295–304.

10). Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10:86–124.

11). Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006; 82(2 Suppl):S15–7.

12). Fischer SA, Avery RK. AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009; 9(Suppl 4):S7–18.

13). Cytomegalovirus. Am J Transplant. 2004; 4(Suppl 10):51–8.

14). Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis. 2001; 32:596–603.

15). Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2008; 16:CD003774.

16). Benmarzouk-Hidalgo OJ, Cordero E, Martí n-Peñ a A, Garcí a-Prado E, Gentil MA, Gomez-Bravo MA, et al. Prevention of cytomegalovirus disease using preemptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther. 2009; 14:641–7.

17). Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006; 6:2134–43.

18). Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008; 8:69–77.

19). Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a metaanalysis comparing prophylactic and preemptive therapies. Clin Infect Dis. 2006; 43:869–80.

20). Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet. 2005; 365:2105–15.

21). Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611–20.

22). Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004; 189:1615–8.

23). Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS. Association of human herpesvirus 7 with cytomegalovirus S disease in renal transplant recipients. Transplantation. 2000; 70:213–6.

24). Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation. 2004; 78:283–5.

25). Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007; 7:2106–13.

26). Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010; 70:965–81.

27). John GT, Manivannan J, Chandy S, Peter S, Fleming DH, Chandy SJ, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc. 2005; 37:4303–5.

28). Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005; 16:1758–74.

29). Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2004; 4(Suppl 10):160–3.

30). Battiwalla M, Paplham P, Almyroudis NG, McCarthy A, Abdelhalim A, Elefante A, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis. 2007; 9:28–32.

31). Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008; 47:804–11.

32). Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008; 46:1455–7.

33). Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after renal transplantation. Am J Kidney Dis. 2001; 37:659–76.

34). Randhawa PS, Finkelstein S, Scantlebury V, Shapiro R, Vivas C, Jordan M, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation. 1999; 67:103–9.

35). Howell DN, Smith SR, Butterly DW, Klassen PS, Krigman HR, Burchette JL Jr, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation. 1999; 68:1279–88.

36). Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation. 2001; 72:1587–92.

37). Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009; 87:621–30.

38). Randhawa P, Ramos E. BK viral nephropathy: an overview. Transplant Rev. 2007; 21:77–85.

39). Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002; 347:488–96.

40). Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005; 79:1277–86.

41). Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis. 2006; 193:80–7.

42). Wali RK, Drachenberg C, Hirsch H. Intensive versus routine care screening for polyoma viral replication (cluster ran-domization) and a road map for stepwise modification of immunosuppression therapy. Am J Transplant. 2008; 8(Suppl 2):283.

43). Hilton R, Tong CY. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother. 2008; 62:855–9.

44). Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis. 1999; 1:50–64.

45). Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003; 17:113–34. viii.

46). Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrió n VS, Barrios C, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis. 1996; 174:583–8.

47). Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331:1325–30.

48). Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997; 24:235–47.

49). Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347:2020–9.

50). Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999; 29:1402–7.

51). Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30:696–709.

52). Outeda Mací as M, Salvador P, Hurtado JL, Martí n I. Tacrolimus-itraconazole interaction in a kidney transplant patient. Ann Pharmacother. 2000; 34:536.

53). Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000; 11(Suppl 15):S1–86.

54). Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS. Primary and reactivated toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med. 1983; 99:27–31.

55). Michaels MG, Wald ER, Fricker FJ, del Nido PJ, Armitage J. Toxoplasmosis in pediatric recipients of heart transplants. Clin Infect Dis. 1992; 14:847–51.